1. Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Renoprotective Effect of Renin-Angiotensin-Aldosterone System Blockade in Patients With Predialysis Advanced Chronic Kidney Disease, Hypertension, and Anemia JAMA Intern Med. 2014;174(3):347-354. doi:10.1001/jamainternmed.2013.12700 Flowchart of Patient SelectionCKD indicates chronic kidney disease; ESA, erythropoiesis-stimulating agent. a Includes angiotensin- converting enzyme inhibitors, angiotensin II receptor blockers, α-blockers, β-blockers, calcium channel blockers, and diuretics. Figure Legend:

2. Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Renoprotective Effect of Renin-Angiotensin-Aldosterone System Blockade in Patients With Predialysis Advanced Chronic Kidney Disease, Hypertension, and Anemia JAMA Intern Med. 2014;174(3):347-354. doi:10.1001/jamainternmed.2013.12700 Cumulative Hazards of Study Outcomes Among Patients With Predialysis Stage 5 Chronic Kidney DiseaseA, Long-term dialysis. B, Composite outcome of long-term dialysis or death. We used the Nelson-Aalen method to calculate the cumulative hazards of both outcomes in users and nonusers of angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin II receptor blockers (ARBs). A multivariate analysis was adjusted for all variables listed in Table 1. P <.001, users vs nonusers. Figure Legend:

3. Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Renoprotective Effect of Renin-Angiotensin-Aldosterone System Blockade in Patients With Predialysis Advanced Chronic Kidney Disease, Hypertension, and Anemia JAMA Intern Med. 2014;174(3):347-354. doi:10.1001/jamainternmed.2013.12700 Adjusted Hazard Ratios (HRs) of Study Outcomes Among Patients With Predialysis Stage 5 Chronic Kidney DiseaseOutcomes include long-term dialysis and the composite outcome of long-term dialysis or death associated with use of angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin II receptor blockers (ARBs). Each factor was adjusted for all other factors listed in Table 1. CCB indicates calcium channel blocker; CHD, coronary heart disease. Figure Legend: